Karyopharm Therapeutics Inc. (44) | Human Resources (22)

Browse by Subcategory

Recent Contracts

Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Filed With SEC on March 29, 2022)
Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
Non-Employee Director Compensation Policy, dated as of May 12, 2021 (Filed With SEC on August 5, 2021)
Retention Agreement dated January 17, 2019, between the Company and Cameron Peters (Filed With SEC on January 18, 2019)
Separation Agreement dated January 17, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)
Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Filed With SEC on March 29, 2022)
Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022 (Filed With SEC on March 1, 2022)
Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 6, 2019)
Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)